Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.86 is 64% above its 5-year average of -2.38, around the middle of its 5-year range (-7.64–7.45).
50.29% above its 12-month average of -1.73.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.28.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:43:05.352Z. Historical observations retain their original dates. Historical series through 2022-03-29.
EARNINGS PER SHARE (EPS)
-0.86
EARNINGS PER SHARE (EPS) AVG TTM
-1.73
EARNINGS PER SHARE (EPS) AVG 3Y
-3.85
EARNINGS PER SHARE (EPS) AVG 5Y
-2.38
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+50.29%
CURRENT VS 3Y AVG
+77.68%
CURRENT VS 5Y AVG
+63.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SAB Biotherapeutics, Inc.
Market Cap
$270.23M
Earnings Per Share (EPS)
-0.86
TTM Avg
-1.73
3Y Avg
-3.85
5Y Avg
-2.38
Market Cap
$270.31M
Earnings Per Share (EPS)
-4.63
TTM Avg
-2.03
3Y Avg
-0.98
5Y Avg
-0.48
Market Cap
$271.00M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
Market Cap
$271.35M
Earnings Per Share (EPS)
-0.17
TTM Avg
-2.37
3Y Avg
-2.73
5Y Avg
-2.69
Market Cap
$267.93M
Earnings Per Share (EPS)
-0.93
TTM Avg
-0.92
3Y Avg
-0.85
5Y Avg
-0.65
Market Cap
$272.78M
Earnings Per Share (EPS)
-1.30
TTM Avg
-1.74
3Y Avg
-1.50
5Y Avg
-1.50
Market Cap
$273.07M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.94M
Earnings Per Share (EPS)
-3.74
TTM Avg
-2.75
3Y Avg
-2.51
5Y Avg
-2.60
Market Cap
$264.74M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $270.23M | -0.86 | -1.73 | -3.85 | -2.38 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | -4.63 | -2.03 | -0.98 | -0.48 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | -1.05 | -1.40 | -1.83 | -1.95 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -0.17 | -2.37 | -2.73 | -2.69 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $267.93M | -0.93 | -0.92 | -0.85 | -0.65 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $272.78M | -1.30 | -1.74 | -1.50 | -1.50 |
| Scribe Therapeutics Inc. (SCTX)vs › | $273.07M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | -3.74 | -2.75 | -2.51 | -2.60 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.74M | -0.48 | -0.82 | -2.37 | -2.68 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.81M | -0.99 | -0.90 | -0.84 | -0.86 |
Trailing EPS (TTM)
$-0.86
Forward EPS (Est.)
$-1.21
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.22 |
| 2024-12-31 | -3.68 |
| 2023-12-31 | -7.64 |
| 2022-12-31 | -4.31 |
| 2021-12-31 | -6.30 |
| 2020-12-31 | 7.45 |
| 2019-12-31 | -0.22 |
